Medical Laboratories & Research
(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod
Laboratory Corporation of America Holdings (LH) received the much awaited nod from the US Federal Trade Commission (FTC) for the proposed acquisition of Orchid Cellmark (ORCH). The FTC nod comes with the rider that LabCorp will have to hive off certain assets of Orchid’s US...
9Dec2011 | vitalstocks | 0 comments | Continued(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again
Laboratory Corporation of America Holdings (LH) has once again extended the tender offer for Orchid Cellmark (ORCH) until December 9, 2011. The company had earlier extended the tender offer to November 30. In May 2011, the company received a request from the Federal Trade Commission...
7Dec2011 | vitalstocks | 0 comments | Continued(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger
Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman & Friedman. The merger was announced in October 2011. PPD shareholders...
6Dec2011 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health to Showcase Key Data
Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX...
1Dec2011 | vitalstocks | 0 comments | Continued(DGX) The Future of Healthcare – Personalized Medicine
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, November 9, 2011: Issue #1639 I just got back from my annual physical. Fortunately, everything was fine. But my experience solidified my belief that one of the major healthcare trends that will emerge is the concept...
10Nov2011 | InvestmentU | 0 comments | Continued(LH) Laboratory Corporation of America Holdings Earnings Scorecard
The announcement of Laboratory Corporation of America Holdings’ (LH) third quarter fiscal 2011 results, as on October 20, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights LabCorp reported adjusted EPS of...
3Nov2011 | vitalstocks | 0 comments | Continued(PPDI) Pharmaceutical Product Development to Go Private
Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman & Friedman for $3.9 billion in cash. PPD shareholders have been offered...
11Oct2011 | vitalstocks | 0 comments | Continued(PPDI) Pharmaceutical Product Development Hires New CEO
Pharmaceutical Product Development, Inc. (PPDI) recently announced the appointment of Mr. Raymond Hill as its new Chief Executive Officer (CEO) and also a member of the Board of Directors effective from September 16. Raymond Hill was the president of IMS Consulting Group at IMS...
24Sep2011 | vitalstocks | 0 comments | Continued(LH) Laboratory Corporation of America Holdings-UnitedHealth Extend Pact
Last week, Laboratory Corporation of America Holdings (LH) announced that it has extended its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group (UNH). The agreement, effective since January 1, 2007, will continue until 2018. Under the terms...
15Sep2011 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Seeks Regular Colon Test
Leading diagnostics player Quest Diagnostics (DGX) is dissatisfied with the outcome of a nationwide study that it had carried out along with the Colon Cancer Alliance. The data demonstrated that one in three of men and women aged 60-70 have been screened for colon cancer only...
29Jun2011 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Launches Gazelle on Android
Quest Diagnostics (DGX),a leading player in the diagnostic testing market, recently launched a new version of its mobile health platform, Gazelle. The company claims that this latest version will work in sync with Google’s (GOOG) fast-growing Android smartphone operating system....
23Jun2011 | vitalstocks | 0 comments | Continued(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer
Laboratory Corporation of America Holdings (LH) has decided to extend the tender offer for Orchid Cellmark (ORCH) till July 15, 2011. Earlier, in May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction....
19Jun2011 | vitalstocks | 0 comments | Continued(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny
Pharmaceutical Product Development, Inc. (PPDI) reported first quarter 2011 earnings of 32 cents per share, above the year-ago earnings of 14 cents per share. Earnings growth was driven by higher revenue, improved gross margins and reduced SG&A expenses. Earnings however...
3May2011 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Expedites Celera Acquisition
Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions are yet to be met. The tender...
15Apr2011 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics – Bear of the Day
Quest Diagnostics (DGX) second-quarter EPS of $0.89 beats the Zacks Consensus Estimate by a penny and the year-ago quarters by 7 cents. However, revenues declined 1.4% to $1.9 billion, driven by a decline in both volume and pricing. Meanwhile, the company proactively negotiated...
2Aug2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Heath Incorporated – Bear of the Day
Genomic Health’s (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company’s lead product, Oncotype DX breast cancer test, recorded a year-over-year growth of 20%, revenues declined sequentially. Meanwhile,...
23Jul2010 | vitalstocks | 0 comments | Continued(LH) LabCorp First Quarter 2010 Earnings Scorecard
First Quarter Highlights On April 21, LabCorp (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared with earnings of $1.22 in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in at $1.30,...
23May2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health’s Loss Wider Than Expected
Genomic Health Inc’s (GHDX) first quarter 2010 loss of 7 cents per share was wider than the Zacks Consensus Estimate of a net loss of 3 cents. The company had suffered a loss of 16 cents in the prior-year period. Total revenues for the reported quarter came in at $41.2 million...
6May2010 | vitalstocks | 0 comments | Continued(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer
Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467 million. Array is entitled to receive $45 million in upfront and milestone payments...
22Apr2010 | vitalstocks | 0 comments | Continued(LH) Laboratory Corporation of America Holdings Misses by a Penny
Laboratory Corporation of America Holdings (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared to earnings of $1.22 reported in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in...
22Apr2010 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Beats Expectations but Revenues are Unchanged
Quest Diagnostics (DGX) reported first quarter fiscal 2010 earnings per share (EPS) of 89 cents, unchanged from the year-ago period. However, excluding the impact of severe weather conditions and charges associated with workforce reduction Quest’s EPS came in at $1.00, beating...
21Apr2010 | vitalstocks | 0 comments | Continued(DGX) Why Healthcare Reform Should Help The Diagnostics Industry
America seems to be divided into two camps… Not blue states versus red states. Not Yankees fans versus Red Sox fans (although why you’d be the latter I’ll never understand). Not even people who support the new healthcare reform bill versus those who are opposed to it. Rather,...
1Apr2010 | InvestmentU | 0 comments | Continued(GHDX) Genomic Health Announces New Distribution Deal
Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to distribute its breast cancer assay Oncotype DX with Palex Medical S.A. in Spain and Portugal. The company also announced encouraging data on Oncotype DX at the 7th European Breast Cancer Conference in Barcelona. The...
29Mar2010 | vitalstocks | 0 comments | Continued(BRLI) Bio-Reference Labs – Analysts React By Raising Estimates
Bio-Reference Labs (BRLI) recently beat earnings estimates once again. Shares are up roughly 10% since being featured as a Zacks Rank Buy in December. Company Description Bio-Reference Laboratories, provides clinical laboratory testing services such as blood and urine analysis...
29Mar2010 | vitalstocks | 0 comments | Continued(SPEX) Initiating Spherix Analyst Coverage at Outperform
We are initiating coverage of Spherix, Inc. (SPEX) with an Outperform rating and price target of $3.50 per share. We are optimistic about D-tagatose, a functional sweetener and a naturally occurring L-epimer of D-Fructose currently under phase III development for the treatment...
9Feb2010 | vitalstocks | 0 comments | Continued(ARRY) Array BioPharma Incorporated Reports Lower Second Quarter Loss
Array BioPharma Inc’s (ARRY) second quarter fiscal 2010 net loss came in at $21.8 million, or 44 cents per share, which was lower than the Zacks Consensus Estimate of a net loss of 55 cents. The company suffered a loss of $37.8 million, or 79 cents a share, in the year-ago...
2Feb2010 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Beats Expectations – Guides In-Line
Quest Diagnostics’ (DGX) fourth quarter earnings per share of 97 cents beat both the Zacks Consensus Estimate by a penny and the 87 cents reported in the year-ago period. Revenues for the quarter increased 2.7% to $1.8 billion. Clinical testing revenues, which account for most...
25Jan2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test
Recently, Genomic Health, Inc. (GHDX) announced the global commercial availability of its Oncotype DX colon cancer test. The 12-gene diagnostic test aims to predict individual recurrence risk in stage II colon cancer patients after surgery. The Genomic Health test is the first...
23Jan2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health Provides Revenue Guidance
Genomic Health, Inc. (GHDX) announced recently that it is confident of meeting the annual revenue guidance for the fiscal year 2009, ended Dec 31. The company expects to report revenues of $149.5 million for fiscal 2009. This represents a 35% increase on revenues of $110.6 million...
8Jan2010 | vitalstocks | 0 comments | Continued(BRLI) Bio-Reference Labs – Earnings Estimates Are Rising
Bio-Reference Laboratories (BRLI) is setting new 52-week highs following its record-breaking quarter. Company Description Bio-Referance Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company...
30Dec2009 | vitalstocks | 0 comments | Continued